Treating Advanced Hepatocellular Carcinoma with Sorafenib: A 10-Year Single Center Experience.

ABSTRACT:

Introduction

Sorafenib was the first therapy used for systemic treatment of unresectable hepatocellular carcinoma (HCC). Multiple prognosis factors associated with sorafenib therapy have been described.

Objectives

The aim of this work was to evaluate survival and time to progression (TTP) on HCC patients treated with sorafenib, and check for predictive factors of sorafenib benefit.

Materials and methods

Retrospectively, data from all HCC patients treated with sorafenib in a Liver Unit from 2008 to 2018 were collected and analyzed.

Results

Sixty-eight patients were included; 80.9% were male, the median age was 64.5 years, 57.4% had Child-Pugh A cirrhosis and 77.9% were BCLC stage C. Macrovascular invasion (MVI) was present in 25% of the patients and 25% of the s

SUBMITTER: Presa Ramos J 

PROVIDER: S-EPMC10305257 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature